Billions of dollars have been invested in healthcare AI. But are we spending in the right places?
The presence of AI in healthcare is rapidly growing – but resource allocation will determine whether the technology has a positive impact.
Related Articles
The antipsychotic drug thiothixene stimulates macrophages to clear pathogenic cells by inducing arginase 1 and continual efferocytosis
Macrophages perform repeated rounds of phagocytosis in response to an FDA-approved dopamine blocker.
Trump throws wrench into NSF’s support for new Texas supercomputer
Spending fight with Congress could force NSF to pull plug on fastest university-based machine
AI drug development’s data problem
The future of drug discovery may be artificial intelligence (AI), but its present is not. AI is in its infancy in the field. To help…
Sexual orientation, gender options cut from U.S. Ph.D. graduate survey
After adding questions to a key survey last year, the U.S. National Science Foundation is reversing course
Make it flow from solid to liquid: Redox-active electrofluids for intrinsically stretchable batteries
A stretchable battery electrode design uses fluids instead of solids to tune its electrochemical and mechanical properties.
Industry Needs More Efficient Viral Vector Production
The main problem is that most vector production technologies were developed for the lab, rather than to support industrial supply,
Precise in vivo RNA base editing with a wobble-enhanced circular CLUSTER guide RNA
Nature Biotechnology – Using G•U wobble base pairs at specific loci increases RNA base-editing precision and efficiency.
Long-Read Sequencing Pinpoints Genetic Basis for Psychiatric Diagnosis in Pediatric Case
Rady study uses PacBio long-read sequencing for RFX3 variant in adolescent patient with autism, showcasing clinical genomics breakthroughs.
Could blocking ‘jumping genes’ help fight disease and aging?
The first clinical trials are testing inhibitors of transposons, DNA sequences that hop around the genome on their own